Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 31

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 31
---
 a supplement to this prospectus that will contain specific information about the terms of that
offering, including the specific amounts, prices and terms of the securities offered. Such prospectus supplements may also add, update
or change information contained in this prospectus. The applicable prospectus supplement will contain information, where applicable, as
to any other listing on the NYSE American or any other securities market or other exchange with respect to the securities covered by such
prospectus supplement.

Our principal executive offices are located at
5005 McConnell Avenue, Los Angeles, California 90066, and our telephone number at that address is (310) 665-2928.

You should read this prospectus and any prospectus
supplement carefully before you invest.

<div align='center'>- 1 -</div>

INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE HEADING “RISK FACTORS” ON PAGE 8 OF THIS PROSPECTUS AND “ITEM 1A—RISK FACTORS” OF OUR MOST RECENT ANNUAL REPORT ON FORM 10-K OR QUARTERLY REPORT ON FORM 10-Q THAT IS INCORPORATED BY REFERENCE IN THIS PROSPECTUS, AS WELL AS THOSE CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND UNDER SIMILAR HEADINGS IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.

This prospectus may not be used to offer or sell any securities unless accompanied by a prospectus supplement.

As of August 13,
2025, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was approximately $26.1
million, based on 11,077,705 shares of outstanding common stock held by non-affiliates as of the date of this prospectus, at a price
of $2.36 per share, which was the last reported sale price of our common stock on the NYSE American on August 11, 2025. Pursuant to
General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement of which
this prospectus is a part in a public primary offering with a value exceeding more than one-third of our public float in